Mirzotamab

CAS No. 2229859-11-2

Mirzotamab( —— )

Catalog No. M37129 CAS No. 2229859-11-2

Mirzotamab is an IgG1κ antibody targeting CD276/B7-H3 and is the naked antibody to Mirzotamab clezutoclax, consisting of 1320 amino acids.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 534 In Stock
10MG 838 In Stock
25MG 1264 In Stock
50MG 1655 In Stock
100MG 2260 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Mirzotamab
  • Note
    Research use only, not for human use.
  • Brief Description
    Mirzotamab is an IgG1κ antibody targeting CD276/B7-H3 and is the naked antibody to Mirzotamab clezutoclax, consisting of 1320 amino acids.
  • Description
    Mirzotamab is an IgG1κ antibody targeting to CD276/B7-H3. Mirzotamab can conjugates with Clezutoclax (HY-137774), an BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Immunology/Inflammation related
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2229859-11-2
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Tolcher A W, et al. A first-in-human study of mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose escalation results. 2021.
molnova catalog
related products